Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes (LOSS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01403571 |
Recruitment Status :
Completed
First Posted : July 27, 2011
Last Update Posted : October 5, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Canadian statistics indicate that the incidence of obesity is increasing and that the occurrence of diabetes in obese individuals is 5-fold greater than those with a healthy weight, making weight control in this population particularly relevant. Preliminary clinical data has shown that the whole grain, Salba, may improve type 2 diabetes control, reduce after-meal blood glucose, cardiovascular disease (CVD) risk factors and suppress appetite. Its use may therefore have potential implications in long-term weight management, while improving diabetes.
The objective of this research (weight loss) is to evaluate whether adding Salba to an energy reduced diet for six months will result in greater weight loss compared to control in overweight and obese individuals with type 2 diabetes. The study recruited 77 overweight or obese individuals with type 2 diabetes. They were instructed to follow a calorie restricted diet and their regular diabetes therapy together with regular exercise. Participants were randomly assigned to receive 30 g Salba/1000 kcal of daily energy requirements, or an oat bran control supplement matched for energy. The effect of the supplements on weight-loss (including waist circumference, % body fat) and glucose control (A1c, fasting glucose levels) will be assessed. In addition, related outcomes such as low-grade body inflammation, hunger-regulating hormones (ghrelin, adiponectin), safety measures (urea, creatinine, ALT and prothrombin time) and satiety scores were evaluated.
Modest weight loss has been associated with improved glucose control in individuals with type 2 diabetes. Addition of Salba to an energy reduced diet may facilitate greater weight loss and improve glycemic control and CVD risk factors compared to such a diet alone. Salba may also promote maintenance of weight loss and therefore help prevent weight gain by providing feelings of fullness that reduce appetite. In light of the high incidence of obesity in individuals with diabetes, Salba grain may be a useful addition to the diet.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus Overweight Obesity | Dietary Supplement: Salba (Salvia hispanica L.) Dietary Supplement: Oat-based Control | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 77 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Whole Grain Salba (Salvia Hispanica L.) on Weight Loss in Overweight and Obese Individuals With Type 2 Diabetes |
Study Start Date : | October 2009 |
Actual Primary Completion Date : | August 2015 |
Actual Study Completion Date : | August 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Salba supplement
30g/1000kal
|
Dietary Supplement: Salba (Salvia hispanica L.)
30g/1000kcal/day over 24 wks |
Placebo Comparator: Oat-bran based Control Supplement
36g/1000kcal
|
Dietary Supplement: Oat-based Control
Placebo: 36g/1000kcal/day over 24 weeks |
- Weight [ Time Frame: 24 weeks ]24 week timeframe for Weightloss phase
- Body composition [ Time Frame: 24 weeks ]24 week timeframe for Weightloss phase
- Blood sugar control [ Time Frame: 24 weeks ](HbA1c and Fasting glucose) 24 week timeframe for Weightloss phase
- Low grade body inflammation [ Time Frame: 24 weeks ]hs-CRP levels
- serum ALT [ Time Frame: 24 weeks ]Safety Measures
- Prothrombin time [ Time Frame: 24 weeks ]Safety Measures
- serum creatinine [ Time Frame: 24 weeks ]Safety Measures
- Blood urea [ Time Frame: 24 weeks ]Safety Measures
- Satiety hormones [ Time Frame: 24 weeks ]ghrelin, adiponectin
- Fatty Acids (% composition) [ Time Frame: 24 weeks ]ALA (18:3 n-3), LA (18:2 n-6); Compliance measure

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Well-controlled type 2 diabetes for at least 1 year
- Treated with diet and/or oral hypoglycemic medications
- BMI 25-40 kg/m2
Exclusion Criteria:
- Weight change in the past three months >10% of body weight
- On insulin therapy
- Unstable angina, myocardial infarction or stroke (within 6 months)
- Planned surgery or pregnancy
- Blood pressure >160mmHg/100mmHg
- Surgical procedures for weight loss and concomitant use of medication or supplements that alter body weight or appetite
- ALA, dietary fibre, fish oil supplements or consuming cold-water fish more than three times per week

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01403571
Canada, Ontario | |
Risk Factor Modification Centre, St. Michael's | |
Toronto, Ontario, Canada, M5B1W8 |
Responsible Party: | Unity Health Toronto |
ClinicalTrials.gov Identifier: | NCT01403571 |
Other Study ID Numbers: |
2103038AJ |
First Posted: | July 27, 2011 Key Record Dates |
Last Update Posted: | October 5, 2016 |
Last Verified: | October 2016 |
Diabetes Mellitus Overweight Weight Loss Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Body Weight Body Weight Changes |